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Background. Falls and fractures in the elderly are among the leading causes of disability. We investigated whether pacemaker
implantation prevents falls in patients with SND in a large cohort of patients. Methods. Patient demographics and medical
history were collected prospectively. Fall history was retrospectively reconstituted from available medical records. The 10-year
probability for major osteoporotic fractures was calculated retrospectively from available medical records using the Swiss fracture
risk assessment tool FRAX-Switzerland. Results. During a mean observation period of 2.3 years after implantation, the rates of
fallers and injured fallers with fracture were reduced to 15% and 6%, respectively. This corresponds to a relative reduction in the
number of fallers of 75% (P < 0.001) and of injured fallers of 63% (P = 0.014) after pacemaker implantation. Similarly, the number
of falls was reduced from 60 (48%) before pacemaker implantation to 22 (18%) thereafter (relative reduction 63%, P = 0.035) and
the number of falls with injury from 22 (18%) to 7 (6%), which corresponds to a relative reduction of 67%, P = 0.013. Conclusion.
In patients with SND, pacemaker implantation significantly reduces the number of patients experiencing falls, the total number of
falls, and the risk for osteoporotic fractures.
1. Background
Falls and fractures are among the leading causes of disability
and loss of independence in the elderly [1]. There are a
variety of causes for falls, some of which have been related to
rhythm disorders such as atrioventricular block [2], carotid
sinus hypersensitivity [3, 4], and sinus node disease (SND)
[2]. Typical clinical manifestations are syncope, bradycardia,
and dizziness. There are data suggesting that pacemaker
implantation reduces falls in the elderly suffering from
atrioventricular block or carotid sinus hypersensititvity, and
hence, it may even decrease healthcare costs [2, 3, 5–7]. On
the other hand, such a reduction in falls and healthcare costs
has not been documented yet in SND, although pacemaker
implantation has been a standard treatment for many years
in this patient group [8].
In an attempt to reduce public healthcare costs caused
by osteoporotic fractures and the morbidity associated with
it, a country-specific fracture risk assessment tool (FRAX
available under http://www.shef.ac.uk/FRAX/tool.jsp?coun-
try=15) was introduced [9, 10] by analyzing characteristics
of patients suffering from osteoporotic fractures. The risk
factors that were used to calculate fracture risk in patients
were identified to be advanced age, female sex, low weight,
previous fracture, among others. By applying this FRAX
assessment tool to patients at risk, 10-year probability for
both hip fracture and other major osteoporotic fractures
can be calculated for each patient individually. Cost-effective
intervention thresholds have been established for some
countries [11, 12].
FRAX is a fracture risk calculator which was developed
by the WHO and calibrated for single countries (more thans
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50 country versions available to date) based on local fracture
epidemiological data. The calculation of the FRAX score
requires the availability of a series of risk factors that predict
the 10-year probability of experiencing a fracture corrected
for remaining life expectancy at a given age. Thus, FRAX is
to bone and fracture risk what the PROCAM or the ESC
scores are to cardiovascular risk. This score could also be used
for highly specific population (such as patients with SND
implanted with a pacemaker), because there is no available
evidence indicating that their fracture risk should be based
on other risk factors than those validated for the general
population (age, BMI, sex, fracture history, parental history
of hip fracture, current smoking, glucocorticoid intake,
rheumatoid arthritis, secondary osteoporosis, excessive alco-
hol consumption, and bone mineral density measured at
the femoral neck). However, FRAX does not assess falls,
an important risk factor for fractures. FRAX and falls are
complementary dimensions of fracture risk, FRAX reflecting
the propensity of bone to fracture and falls representing
the inaugural event that may lead to a subsequent fracture,
especially in patients with high FRAX scores.
Conceptually, SND patients are at increased risk for
fractures andmight benefit from therapies aimed at reducing
this risk such as pacemaker implantation. Indeed, for
cardiovascular disease in general there is evidence for a
link to osteoporosis [13, 14]. Whether or not pacemaker
implantation prevents falls in patients with SND, however,
remains unproven. We therefore aimed to investigate the
effects of pacemaker implantation on future fractures in
patients with SND using the FRAX tool in a consecutive
cohort seen at a single tertiary care center. Specifically, it was
the aim of the present analysis to define the characteristics of
SND patients, including their fall incidence one year before
and after pacemaker implantation. The primary objective
was to evaluate and compare the extent of the risk reduction
in falls with and without injury. As secondary objectives, we
determined the fracture risk profile and the ten-year fracture
risk in SND patients based on the validated FRAX algorithm
[9, 10].
2. Methods
2.1. Patients. The electronic patient database of the Clinic for
Cardiology of the University Hospital of Zurich, Switzerland,
was searched for patients with a diagnosis of SND who
were implanted a pacemaker and had follow-ups in the
outpatient cardiology setting between January 1, 1996, and
December 31, 2009. Patient demographics, general medical
history, cardiovascular disease history including surgery and
arrhythmia, symptoms, and cardiovascular drug therapy
were collected prospectively and analyzed retrospectively.
Only patients with a diagnosis of SND who were implanted a
pacemaker and had followups in the outpatient cardiology
setting between January 1, 1996, and December 31, 2009,
were included. Generally the patient’s medication was not
substantially changed after pacemaker implantation. The
diagnosis of SND and the controls were made by Holter ECG
and after pacemaker implantation by pacemaker control. The
implantation of pacemaker in SND patients and the avail-
ability of the data represent all the inclusion criteria. Written
consent was given by the patients for their information to
be stored in the hospital database and used for research. The
cantonal ethics committee of canton Zurich acknoweledged
the consent to use the data for the research.
Table 1 shows the baseline characteristics of the patients
included in the study.
2.2. Fall History. In our study we used the WHO definition
of fall (inadvertently coming to rest on the ground, floor, or
other lower level, excluding intentional change in position
to rest in furniture, wall, or other objects). The patients
were personally interviewed in a standardised manner, using
the WHO definiton of fall. Fall history was retrospectively
reconstituted from the medical records. The falls after
pacemaker implantation were documented by using the
same proceeding as before pacemaker implantation (patients
personally interviewed using the WHO definition of fall).
For fracture falls there was a confirmation by imaging.
The 10-year probability for hip and any major osteoporotic
fracture was calculated retrospectively from availablemedical
records using the Swiss fracture risk assessment tool FRAX-
Switzerland.
2.3. Statistical Analysis. Descriptive statistical methods were
used to calculate the prevalence of patient characteristics in
the SND population (mean, standard deviation). Predictors
of falls before pacemaker implantation were identified by
an exploratory multiple regression analysis. The incidence
and rate of falls with and without injury before and after
pacemaker implantation were compared with a paired t-
test. The level of statistical significance was defined as a
two-sided P less than 0.05. The following parameters were
used in the multiple regression model aimed at identifying
predictors of falls during the 12months before pacemaker
implant: age, height, weight, BMI, office-based heart rate,
and LVEF; clinical signs and symptoms (syncope, fatigue,
dizziness, dyspnea, bradycardia); drug therapy by therapeutic
class (anticoagulants, class I and III antiarrhythmics, ACE
inhibitors or ARBs, beta-blockers, cardiac glycosides, diuret-
ics, vasodilators); presence of persistent or paroxysmal atrial
and/or ventricular arrhythmia; presence of atrioventricular
conduction disorders; history of ablation, coronary artery
surgery, or valve surgery; history of cardiovascular disease
(cardiomyopathy, coronary artery disease, valve dysfunction,
stroke, hypertension). All calculations were done with the
statistical software StatsDirect version 2.7.8 (StatsDirect Ltd,
Altrincham, Cheshire, UK).
3. Results
3.1. Patient Cohort. A total of 1803 patients underwent
pacemaker implantation at our institution. Of these, 164
(9.1%) had SND and were regularly seen for a follow-
up as outpatients. Patients implanteding a PM at the
University Hospital are usually referred back to their treating
cardiologist. However, patients who were not referred to
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Table 1: Baseline characteristics of included patients.
Mean SD Range (min–max)
Age at PM implantation (years) 71.9 9.7 45–94
LVEF (%) 55.9 13.3 20–77
Height (cm) 168.8 10.5 142–195
Weight (kg) 73.5 13.9 42.5–111
BMI 25.7 3.7 17.1–38.7
Heart rate at rest (bpm) 66.8 25.3 28–180
FRAX available (N = 134)
10-year risk of hip fracture 5.5 7.0 0.1–58
10-year risk of major osteoporotic fractures 14.5 10.6 2.9–64
N %
Total 40+ 150 100.0
Male sex 91 60.7
Diabetes mellitus 25 16.7
Ever smoked 56 37.3
NYHA class
No heart failure 46 30.7%
NYHA I 39 26.0%
NYHA II 37 24.7%
NYHA III 22 14.7%
NYHA IV 6 4.0%
the University hospital by a cardiologist in private practice
and those who decided to continue followup directly at the
University hospital are those we see on regular basis for
followup as outpatients and of whom we have complete
records. All these patients had 2 clinical controls combined
with pacemaker controls per year. These were included in
the analysis. From 164 patients with SND who implanted
a PM, only patients aged 40+ were included in the analysis
(of which the youngest was 45 years old, 32 patients were
>65 years old (23.3%)). Thirteen patients below 40 years
of age were excluded. In addition, a 61-year-old “frequent
faller” (who presented 80 falls during the year before PM
implantation, more than half of all recorded falls) was
excluded from the analysis for statistical reasons. Thus 150
patients were included in the baseline characteristics analysis.
Additional 26 patients were excluded from the fall
analysis, because of missing follow-up data for falls during
at least 12months since pacemaker implantation (Figure 1).
Therefore, a total of 150 patients were included in the
descriptive analysis for patient characteristics and 124 in the
fall history analysis (Table 1).
150 patients (61% male) fulfilling the criteria were
included for a descriptive analysis of the baseline charac-
teristics (Figure 1). Mean age at the time of implantation
was 71.9 ± 7.9 years. The prevalence of diabetes mellitus
was 16.7%. 37.0% of the patients were current or past
smokers. All patients had a history of cardiovascular pathol-
ogy, including coronary artery disease (41.3%), valvular
dysfunction (34.7%), and cerebrovascular disease (14.7%).
Prevalence of hypertension was high (87.4%) while symp-
tomatic hypertension was rarely observed (3.6%). 55 patients
(36.4%) had cardiac interventions, thereof catheter ablation
5.3%, coronary intervention 17.9%, and valve surgery 15.2%.
The patients included were diagnosed to have SND in
the presence of the following clinical findings: sinus arrest
or sinus pause 44.7%, bradycardia/tachycardia syndrome
54.7%, sinus bradycardia 78.7%, and chronotropic incompe-
tence 10%, which in turn triggered symptoms characteristic
for SND: dizziness 39%, syncope 35%, dyspnea 28%, and
fatigue 23%.
3.2. Medications. All patients were treated with cardio-
vascular drugs, most frequently anticoagulants including
acetylsalicylic acid (78%), followed by angiotensin convert-
ing enzyme inhibitors or angiotensin II receptor antago-
nists (50%), beta-adrenergic receptor blockers (34%), and
diuretics (29%). Less commonly used medications were
antiarrhythmics including calcium channel blocking agents,
vasodilators, and cardiac glycosides.
3.3. FRAX Analysis. In 134 (89%) patients with SND enough
information in patient history to calculate the FRAX score
could be gathered, resulting in a mean 10-year risk for hip
fracture of 8.7% and 3.7% for women and men, respectively.
This corresponds to a twofold increase of hip fracture
risk compared to age-, sex-, and BMI-matched individuals
without additional risk factors. FRAX analysis also showed
that 65% of the female and 56% of the male patients had
an individual 10-year probability for hip fracture that was
3.0% ormore, therefore exceeding the intervention threshold
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Excluded from analysis
Patients without sinus node
Patients with SND not followed
as outpatients at the USZ
N = 377
Patients aged 3–25 years
N = 13
“Frequent faller”
N = 1
Patients with no follow-up visit
data available
N = 26
Patients implanted a pacemaker between 1996 and
2010 at the Cardiovascular Center of the University
Hospital of Zurich
Patients implanted a pacemaker because of sinus
node disease between 1996 and 2010 and
regularly followed up at the USZ
Patients aged 40 years or more
(baseline characteristics/descriptive analysis)
N = 150
Patients with longitudinal follow-up data >12
months after PM implant
(fall history before versus after PM implant
predictors of falls)
N = 124
N = 1803
N = 164
disease N = 1262 (70%)
Figure 1: Consort table documenting patient disposition based on inclusion and exclusion criteria.
of 3% defined as cost-effective by the National Osteoporosis
Foundation in the USA [11, 12] (Figure 2).
The intervention threshold for the 10-year probability of
suffering any osteoporotic fracture in turn was defined as
10% or higher, which was again exceeded by 70% of female
and 36% of male patients in our analysis.
3.4. Predictors of Falls. Only two statistically significant
predictors of falls in SND patients could be identified in
the multiple regression analysis: treatment with a diuretic
(r = 0.26, P = 0.005) and history of syncope (r = 0.6,
P < 0.001). The fact that falls are frequent in patients with
syncope is not surprising, while with diuretic treatment it can
be argued that such patients are more likely to suffer from
hypotensive episodes.
3.5. Documented Falls. Of the 124 patients with available
follow-up data, 40 (32%) had experienced at least one fall
in the 12 months preceding pacemaker implantation. Of
those 19 (47.5% of fallers, 15.3% of total) had acquired an
injury while falling. During amean 2.3 years of followup after
pacemaker implantation, the number of falls was reduced to
10 patients (8.1%) falling and 7 (70% of fallers, 5.6% of total)
suffering injury while falling. This corresponds to a relative
reduction in the number of fallers by 75% (P < 0.001) and of
injured fallers by 63% (P = 0.014; Figure 3).
Considering the number of falls rather than the number
of patients falling, a similar effect could be observed. Indeed,
the number of falls was reduced from 60 before pacemaker
implantation to 22 thereafter and the number of falls with
injury from 22 to 7, which corresponds to a relative risk
reduction of 63% (P = 0.035) and 67% (P = 0.013)
respectively (Figure 4).
One patient was excluded from the analysis because he
was a “frequent faller.” However, the beneficial effect of
pacemaker implantation on the number of falls could also be
observed in this particular case, as the patient experienced 80
falls during the 12months preceding pacemaker implanta-
tion, a number which was reduced eightfold to 10 falls during
the 12months following pacemaker implantation.
4. Discussion
Our study is the first, to our knowledge, to evaluate the
effect of pacemaker implantation on the incidence of falls
and fractures which had been diagnosed with SND. Our
findings suggest that pacemaker therapy is highly effective
in preventing falls and resultant fracture injuries in this
patient population who were mostly elderly. Indeed, using
a novel statistical analysis we found that during a follow-
up period of over 2 years, the implantation of a pacemaker
reduced the rates of falls and fracture injuries to 15% and 6%,
respectively. This corresponds to a relative risk reduction in
the number of fallers of 75% and of injured fallers of 63%.
Similarly, the absolute number of falls was reduced from 60
to 22 and the number of falls with injury from 22 to 7.
Falls are an important problem in elderly patients
causing a significant number of unplanned hospitalizations,
operations (mainly hip replacement) and invalidity, and
eventually nursing-home care [13–15]. Accordingly, the costs
of falls are considerable and their causes are numerous [16].
As expected the mean age of the patients included in this
study averaged more than 70 years and many of them had
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Figure 2: 10-year probability for a hip fracture assessed by FRAX in women and men with sinus node disease.
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Figure 3: Number of patients experiencing at least one fall before and reduction of falls after pacemaker implantation for sinus node disease.
(RRR: relative risk reduction).
considerable comorbidities such as diabetes, valvular heart,
coronary artery disease, and/or cerebrovascular disease.
Not all falls are preventable by medical measures, but
some are, particularly those related to bradycardias [17].
Pacemakers have been used for this indication ever since
their introduction by senning in the late 1950s [18, 19]. The
current study, however, documented for the first time the
amount of benefit provided by this therapy in the prevention
of falls in patients with SND using the Swiss fracture
risk assessment tool FRAX-Switzerland. Within the entire
registry of 1803 pacemaker implantations at our institution,
those for SND amounted to about 10% of all patients.
The World Health Organization (WHO) defined osteo-
porosis as “a systemic skeletal disease characterized by
6 Cardiology Research and Practice
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Figure 4: Fall rate before and after pacemaker implantation for sinus node disease. (RRR = relative risk reduction).
low bone mass and microarchitectural deterioration of
bone tissue, with a consequent increase in bone fragility
and susceptibility to fracture” [20]. The most frequent
complications of the disease are the typical osteoporotic
fractures occurring at the hip, spine, distal forearm, and
proximal humerus commonly referred to as major osteo-
porotic fractures [21]. In 50-year-old Swiss men and women,
the remaining lifetime probabilities of presenting a major
osteoporotic fracture were 20.2% and 51.3%, respectively
[9]. Between years 2000 and 2007, the burden of hospitalized
osteoporotic fractures to the Swiss healthcare system has
continued to increase in both sexes in Switzerland, driven
by an increasing number and incidence of hospitalizations
for nonhip fractures, although the incidence of hip fractures
has declined [22]. Furthermore, in women, this burden was
significantly higher than that of major cardiovascular events
(acute myocardial infarction, stroke, and heart failure) and
the gap widened over time [23]. Low bonemass, as measured
by DXA, is a key predictor of fracture risk [24–27]. However,
bone mineral density (BMD) alone does not capture all
determinants of fracture probability [28]. Recently, the use
of clinical risk factors alone or in combination with BMD has
been shown to predict the probability of hip and osteoporotic
fractures in men and women [29]. In order to identify the
major clinical risk factors for osteoporotic fracture, the data
from nine prospective primary cohorts and 11 prospective
validation cohorts, including more than 275,000 persons
corresponding to 1.4 million person-years with more than
22,711 reported fractures, were analysed [29]. The valida-
tion analysis included the results from the Swiss SEMOF
cohort [30]. In addition to any prior fragility fracture that
occurred after age 50, age, sex, body mass index, and
additional risk factors were considered. These included prior
use of glucocorticoids, secondary osteoporosis, rheumatoid
arthritis, a parental history of hip fracture, current cigarette
smoking, and alcohol intake of three or more units/day.
These factors were identified as clinical predictors of osteo-
porotic fracture probability, independently of BMD [29].
Taking into account local epidemiological data, the impact
of these risk factors on the 10-year absolute probability of
having a fracture can allow for country-specific prediction
of individual fracture probability, based on the individual
risk factor profile. This case-finding algorithm, known as
FRAX (http://www.shef.ac.uk/FRAX/), has been developed
in collaboration with the WHO and has been customized to
the epidemiology of several countries including Switzerland
[10].
In the present analysis, most of the patients who under-
went pacemaker implantation for SND were at increased
risk for major fractures, as assessed by their FRAX score.
Pacemaker implantation significantly decreased the fall rate
and thereby the number of initial events generally required
for a subsequent fracture.
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